Blau Farmacêutica posted record 3Q24 results with 31% revenue growth, margin expansion, and strong cash flow, driven by the Hospital Segment and new product launches. Integration of Bergamo and ongoing investments support a positive outlook.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.